| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A left pleural effusion with a calcified tumoral mass and left hemithoracic uptake on bone scan
|
Quoix, Elisabeth
|
|
2001
|
32 |
2 |
p. 203-205
3 p.
|
artikel
|
| 2 |
An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer
|
van Sörnsen de Koste, John
|
|
2001
|
32 |
2 |
p. 145-153
9 p.
|
artikel
|
| 3 |
Asbestos fiber burdens in lung tissues of Hong Kong Chinese with and without lung cancer
|
Liu, Yungang
|
|
2001
|
32 |
2 |
p. 113-116
4 p.
|
artikel
|
| 4 |
Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation
|
Rodrigus, Patrick
|
|
2001
|
32 |
2 |
p. 129-136
8 p.
|
artikel
|
| 5 |
Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer
|
Horvath, Lisa
|
|
2001
|
32 |
2 |
p. 173-178
6 p.
|
artikel
|
| 6 |
Combination chemotherapy for extensive small cell lung cancer — experience from India
|
Behera, D.
|
|
2001
|
32 |
2 |
p. 207-208
2 p.
|
artikel
|
| 7 |
Common European Strategy for Screening of Lung Cancer?
|
|
|
2001
|
32 |
2 |
p. 211-
1 p.
|
artikel
|
| 8 |
Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer
|
Vassilakopoulos, Theodoros
|
|
2001
|
32 |
2 |
p. 137-144
8 p.
|
artikel
|
| 9 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
|
Kakolyris, S.
|
|
2001
|
32 |
2 |
p. 179-187
9 p.
|
artikel
|
| 10 |
Localised spontaneous regression in mesothelioma — possible immunological mechanism
|
Robinson, B.W.S.
|
|
2001
|
32 |
2 |
p. 197-201
5 p.
|
artikel
|
| 11 |
Metabolic genetic polymorphisms and susceptibility to lung cancer
|
Bouchardy, Christine
|
|
2001
|
32 |
2 |
p. 109-112
4 p.
|
artikel
|
| 12 |
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer — the use of complete response rate as the primary endpoint in phase II trials
|
Dowlati, Afshin
|
|
2001
|
32 |
2 |
p. 155-162
8 p.
|
artikel
|
| 13 |
Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma
|
Gajra, Ajeet
|
|
2001
|
32 |
2 |
p. 189-196
8 p.
|
artikel
|
| 14 |
Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol®) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer
|
Willner, Jochen
|
|
2001
|
32 |
2 |
p. 163-171
9 p.
|
artikel
|
| 15 |
Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer
|
Dingemans, Anne-Marie C
|
|
2001
|
32 |
2 |
p. 117-128
12 p.
|
artikel
|
| 16 |
Yes! Time for global strategy to improve the treatment of lung cancer is right now
|
Jeremic, B.
|
|
2001
|
32 |
2 |
p. 209-210
2 p.
|
artikel
|
Tijdschrift beschrijving